SCHEMBL643004

SCHEMBL643004

O=C(O)C1Cc2ccccc2N1S(=O)(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PTGER3 P43115 1/20 0.47
MCL1 Q07820 3/20 0.46
LMNA P02545 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD11B1 P28845 1/20 0.45
BDKRB1 P46663 1/20 0.45
CCR2 P41597 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL644139 0.86 ALDH1A1 (0.47) ALDH1A1TDP1L3MBTL1PTGER3LMNA
SCHEMBL5253603 0.86 MMP8 (0.53) ALDH1A1TDP1L3MBTL1MCL1LMNA
SCHEMBL27440114 0.85 LMNA (0.47) ALDH1A1TDP1L3MBTL1PTGER3MCL1
SCHEMBL28751377 0.84 LMNA (0.52) ALDH1A1TDP1L3MBTL1PTGER3MCL1
SCHEMBL21183354 0.84 MCL1 (0.64) ALDH1A1PTGER3MCL1LMNA
SCHEMBL2489104 0.83 L3MBTL1 (0.47) ALDH1A1TDP1L3MBTL1MCL1LMNA
SCHEMBL927220 0.82 BDKRB1 (0.51) PTGER3MEN1KMT2ABDKRB1
SCHEMBL13986553 0.82 MCL1 (0.62) TDP1L3MBTL1MCL1LMNA
SCHEMBL927698 0.82 ESR1 (0.57) ALDH1A1TDP1L3MBTL1PTGER3MCL1
SCHEMBL15280428 0.81 LMNA (0.67) ALDH1A1TDP1L3MBTL1MCL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119633-B2 N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases GRUENENTHAL GMBH (DE) 2012-02-21 US disclosed
EP-2150530-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-10-26 EP disclosed
EP-2150530-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-02-10 EP disclosed
US-20080312231-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
WO-2008131947-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312231-A1 Substituted Sulfonamide Compounds SULT2A1, SULT1A1, SCN1A ALDH1A1 511/4885TDP1 4140/4885L3MBTL1 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.